SEC Company Response from Viking Therapeutics, (VKTX) — Dec 29, 2017
Viking Therapeutics, Inc.
Date: Dec. 29, 2017 · CIK: 0001607678 · Accession: 0001564590-17-025382
AI Filing Summary & Sentiment
File numbers found in text: 333-222202
Letter
vktx-corresp.htm
Viking Therapeutics, Inc.
12340 El Camino Real, Suite 250
San Diego, CA 92130
December 29, 2017
VIA EDGAR
Securities and Exchange Commission
100 F Street, N.E.
Washington, D.C. 20549
Re:
Viking Therapeutics, Inc.
Registration Statement on Form S-1
Filed December 20, 2017
File No. 333-222202
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended, Viking Therapeutics, Inc. (the “Registrant”) hereby respectfully requests that the effectiveness of the Registration Statement on Form S-1 (File No. 333-222202) of the Registrant (the “Registration Statement”), filed with the Securities and Exchange Commission (the “Commission”) on December 20, 2017, be accelerated so that it will be declared effective at 4:30 p.m., Eastern Time, on January 3, 2018 or as soon thereafter as may be practicable. There are no underwriters for this proposed offering, which is an offering of the Registrant’s common stock by the selling stockholders.
The Registrant hereby confirms that it is aware of its responsibilities under the Securities Act of 1933, as amended, and the Securities Exchange Act of 1934, as amended, as they relate to the proposed offering of the securities specified in the Registration Statement.
It would be appreciated if, promptly after the Registration Statement has become effective, you would so inform our outside counsel, Jeffrey T. Hartlin of Paul Hastings LLP, by telephone at (650) 320-1804 or by email at jeffhartlin@paulhastings.com. The Registrant hereby authorizes Mr. Hartlin to orally modify or withdraw this request for acceleration.
Sincerely,
VIKING THERAPEUTICS, INC.
Show Raw Text
CORRESP 1 filename1.htm vktx-corresp.htm Viking Therapeutics, Inc. 12340 El Camino Real, Suite 250 San Diego, CA 92130 December 29, 2017 VIA EDGAR Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Re: Viking Therapeutics, Inc. Registration Statement on Form S-1 Filed December 20, 2017 File No. 333-222202 Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as amended, Viking Therapeutics, Inc. (the “Registrant”) hereby respectfully requests that the effectiveness of the Registration Statement on Form S-1 (File No. 333-222202) of the Registrant (the “Registration Statement”), filed with the Securities and Exchange Commission (the “Commission”) on December 20, 2017, be accelerated so that it will be declared effective at 4:30 p.m., Eastern Time, on January 3, 2018 or as soon thereafter as may be practicable. There are no underwriters for this proposed offering, which is an offering of the Registrant’s common stock by the selling stockholders. The Registrant hereby confirms that it is aware of its responsibilities under the Securities Act of 1933, as amended, and the Securities Exchange Act of 1934, as amended, as they relate to the proposed offering of the securities specified in the Registration Statement. It would be appreciated if, promptly after the Registration Statement has become effective, you would so inform our outside counsel, Jeffrey T. Hartlin of Paul Hastings LLP, by telephone at (650) 320-1804 or by email at jeffhartlin@paulhastings.com. The Registrant hereby authorizes Mr. Hartlin to orally modify or withdraw this request for acceleration. Sincerely, VIKING THERAPEUTICS, INC. By: /s/ Brian Lian, Ph.D. Brian Lian, Ph.D. President and Chief Executive Officer cc:Jeffrey T. Hartlin, Esq. (Paul Hastings LLP)